Effectiveness of Closed System Drug Transfer Devices in Reducing Leakage during Antineoplastic Drugs Compounding

Maria Teresa Piccardo, Alessandra Forlani and Alberto Izzotti
Additional contact information
Maria Teresa Piccardo: IRCCS Ospedale Policlinico San Martino, Mutagenesis & Cancer Prevention Unit, 16132 Genova, Italy
Alessandra Forlani: IRCCS Ospedale Policlinico San Martino, Mutagenesis & Cancer Prevention Unit, 16132 Genova, Italy
Alberto Izzotti: IRCCS Ospedale Policlinico San Martino, Mutagenesis & Cancer Prevention Unit, 16132 Genova, Italy

IJERPH, 2021, vol. 18, issue 15, 1-10

Abstract: This study, conducted in a centralized cytotoxic drug preparation unit, analyzes the effectiveness of two closed system drug transfer devices (CSTDs) in reducing leakage during antineoplastic drug compounding. Wipe/pad samplings inside and outside the preparation area were taken during surveillance programs from 2016 to 2021. All samples were analyzed for gemcitabine (GEM) contamination. In 2016, the presence of GEM in some samples and the contamination of the operators’ gloves in the absence of apparent drug spilling suggested unsealed preparation systems. In subsequent monitoring, GEM was also evaluated in the vial access device and in the access port system to the intravenous therapy bag of Texium TM /SmartSite TM and Equashield ® II devices after the reconstitution and preparation steps of the drug. The next checks highlighted GEM dispersion after compounding using Texium TM /SmartSite TM , with positive samples ranging from 9 to 23%. In contrast, gemcitabine was not present at detectable levels in the Equashield ® II system in all of the evaluated samples. The Equashield ® II closed system seems effectively able to eliminate spills and leakage during gemcitabine compounding. Since drugs with different viscosities can have different effects on CSTDs, Equashield ® II needs to be considered with other antineoplastic drugs during a structured surveillance program.

Keywords: closed system drug transfer device; antineoplastic drugs; drug compounding; gemcitabine; environmental monitoring (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2021
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/18/15/7957/pdf (application/pdf)
https://www.mdpi.com/1660-4601/18/15/7957/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:18:y:2021:i:15:p:7957-:d:602872

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().